与阿尔茨海默病相关的血结合的粉样β的活性部位环境
Debajyoti Pramanik1, Somdatta Ghosh Dey
1Department of Inorganic Chemistry, Indian Association for the Cultivation of Science, Jadavpur, Kolkata, India 700032.
Journal of the American Chemical Society
|December 15, 2010
概括
阿尔茨海默病涉及血与粉样β (Aβ) 结合. 关键的残留物,histidine 13和arginine 5,对于heme-Aβ复合体的形成和过氧化酶活性至关重要,可能解释AD病理.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默氏病 (AD) 与时间大脑中的血增加有关.
- 血与β-粉样蛋白 (Aβ) 结合,形成导致AD病理的复合物,包括铁失调和氧化应激.
研究的目的:
- 为了描述Aβ中的血结合活性位点.
- 为了确定参与heme-Aβ复合体形成和过氧化酶活性的关键残留物.
主要方法:
- 利用野生型和突变的Aβ来研究血红蛋白相互作用.
- 在heme-Aβ复合体上进行过氧化酶测定和pH扰动.
主要成果:
- 在生理条件下确定了histidine 13 (His13) 和histidine 14 (His14) 作为血结合残留物.
- 确定氨酸5 (Arg5) 是一个关键的第二球残留物,对于血红-Aβ复合物的过氧化酶活性至关重要.
- 观察到His13和Arg5在动物中不存在,它们不会表现出AD.
结论:
- 这项研究阐明了heme-Aβ活性部位的分子细节.
- His13和Arg5在heme-Aβ复合体形成和过氧化酶活性中起着重要作用,这使得它们与阿尔茨海默病的病原发生有关.
- 在动物中缺乏这些残留物可能解释了它们缺乏AD病理.
相关概念视频
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...


